Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01768338 · ClinicalTrials.gov registry record · Phase 1
Recombinant Human IL-18 and Ofatumumab After PBSCT for Lymphoma
A Phase 1 study of Non-Hodgkin's Lymphoma, sponsored by Michael John Robertson.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT01768338: Completed Phase 1 study of Non-Hodgkin's Lymphoma, sponsored by Michael John Robertson.
NCT01768338 is a Phase 1 study of Non-Hodgkin's Lymphoma that has completed, run by Michael John Robertson. The registered enrollment target is 9 participants, below the 222-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01768338, a Phase 1 study of Non-Hodgkin's Lymphoma, has completed, sponsored by Michael John Robertson.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test the safety of rhIL-18 combined with ofatumumab to see what effects (good and bad) it has on subjects and their non-Hodgkin's lymphoma.
Primary Outcome
Adverse events will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0 which uses a scale of 1 (mild) to 5 (caused death).
Conditions Studied
Interventions
- DRUG Ofatumumab combined with SB-485232
Study Locations (1)
Indiana
- Indiana University Melvin and Bren Simon Cancer Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2013-02 |
| Est. Completion | 2017-08-03 |
| Phase | Phase 1 |
What the finished NCT01768338 record still lists
NCT01768338 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 222-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Non-Hodgkin's Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Ofatumumab combined with SB-485232 is the first listed.
NCT01768338 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT01768338 about?
NCT01768338 is a clinical study titled "Recombinant Human IL-18 and Ofatumumab After PBSCT for Lymphoma". The purpose of this study is to test the safety of rhIL-18 combined with ofatumumab to see what effects (good and bad) it has on subjects and their non-Hodgkin's lymphoma.
What is the current status of trial NCT01768338?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2013-02. Estimated completion is 2017-08-03.
What conditions does trial NCT01768338 study?
This clinical trial studies the following conditions: Non-Hodgkin's Lymphoma.
What interventions are being tested in trial NCT01768338?
The interventions under investigation include: Ofatumumab combined with SB-485232 (DRUG).
Who is sponsoring clinical trial NCT01768338?
This trial is sponsored by Michael John Robertson, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01768338 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin's Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01768338's enrollment target sits among peer trials
9 61st of 63 higher than 3 of 63 other Non-Hodgkin's Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Hodgkin's Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
RECRUITING · Phase 1
-
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma
RECRUITING · Phase 1
-
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
RECRUITING · Phase 1
-
Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia